Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.61 |
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946967 | 1.00 | MAPK14 (0.61) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL15946968 | 0.87 | MAPK14 (0.59) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL18165003 | 0.87 | MAPK14 (0.69) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL15946969 | 0.87 | MAPK14 (0.60) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL15947037 | 0.84 | MAPK14 (0.79) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL15947036 | 0.84 | MAPK14 (0.65) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL19669137 | 0.77 | MAPK14 (0.61) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL15946946 | 0.76 | MAPK14 (1.00) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL14691192 | 0.76 | MAPK14 (0.68) | MAPK14BRAFRAF1YES1ALDH1A1 | |
| SCHEMBL15939405 | 0.75 | MAPK14 (0.61) | MAPK14BRAFRAF1YES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | MAPK14 113/4885BRAF 49/4885RAF1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.